EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study

Xiaoyi Feng, Xiaoyan Liu, Hui Guan, Chunhong Chen, Feng Gao, Xiaoxing Gao, Minjiang Chen iD, Jing Zhao, Yan Xu iD, Mengzhao Wang

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70043 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Xiaoyi Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High-Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study explored the safety and efficacy of combining radiotherapy with sintilimab in non‐small cell lung cancer (NSCLC) patients who have progressed after first or second‐line therapy.

Methods

In this multicenter, single‐arm trial, patients with NSCLC who had progressed after first or second‐line therapy were enrolled. Participants received hypofractionated stereotactic body radiotherapy (SBRT) (requiring a single‐site biological dose of more than 30 Gy or planned to reach 30 Gy) followed by sintilimab every 3 weeks until disease progression or unacceptable toxicity occurred.

Results

From March 1, 2019, to July 27, 2023, 14 patients were enrolled across two centers. The cohort included 64.3% males and 35.7% females, with a median age of 67 years (range 57–73 years). All participants completed radiation therapy and received at least one cycle of sintilimab. The overall response rate (ORR) was 21.4% (3/14) and the disease control rate (DCR) was 71.4% (10/14). The absent radiation response (ARR) was 14.3% (2/14). The median PFS was 4.17 months (95% CI: 1.15–8.69 months), with a 6‐month PFS rate of 42.9%. The median OS was 16.17 months (95% CI: 11.69–20.64 months). Overall, 10 patients (71.4%) experienced at least one treatment‐emergent adverse event (TEAE). Grade 3 adverse events included one case each of immune‐related myocarditis, thrombocytopenia, and checkpoint inhibitor pneumonitis (CIP). Four patients (28.6%) had immune‐related adverse events (irAEs) including skin rash and pruritus (2/14, grade 1), immune‐related myocarditis (1/14, grade 3), and CIP (1/14, grade 3).

Conclusions

Radiotherapy combined with sintilimab for NSCLC patients who progressed after first‐or second‐line therapy showed promising efficacy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsAgedFemaleHumansMaleMiddle AgedProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

adenocarcinomaimmunotherapynon‐small cell lung cancerradiotherapysintilimabsquamous cell carcinoma

Substanzen

Antibodies, Monoclonal, Humanizedsintilimab

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
  • Department of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
  • Department of Oncology, Beidahuang Group General Hospital, Heilongjiang, People's Republic of China.

ORCID-Profile: Minjiang Chen, Yan Xu

Förderung

  • National High-Level Hospital Clinical Research Funding

Zitieren

APA

Feng, X., Liu, X., Guan, H., Chen, C., Gao, F., Gao, X., Chen, M., Zhao, J., Xu, Y., & Wang, M. (2025). Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70043

Vancouver

Feng X, Liu X, Guan H, Chen C, Gao F, Gao X, et al. Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70043

BibTeX
@article{Feng2025,
  author = {Feng, Xiaoyi and Liu, Xiaoyan and Guan, Hui and Chen, Chunhong and Gao, Feng and Gao, Xiaoxing and Chen, Minjiang and Zhao, Jing and Xu, Yan and Wang, Mengzhao},
  title = {Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70043}
}
Kostenlos starten →